|
|
| (81 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| − | {{tp|p=32362782|t=2020. Aktuelle Informationen zu COVID-19 auf einer Plattform ? zeitschriftenübergreifend |pdf=|usr=}}
| + | |
| − | *[https://www.gisaid.org/ GISAID database on covid19]
| + | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| − | *'''[[Reviews on covid19 disease]]'''
| |
| − | {{tp|p=32330209|t=ä. A precision medicine approach to managing 2019 novel coronavirus pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32278960|t=2020. COVID-19 from veterinary medicine and one health perspectives: What animal coronaviruses have taught us |pdf=|usr=}}
| |
| − | {{tp|p=32345483|t=ä. CCOVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause |pdf=|usr=}}
| |
| − | {{tp|p=32334862|t=ä. COVID-19�: caract�ristiques cliniques, biologiques et radiologiques chez l?adulte, la femme enceinte et l?enfant Une mise au point au c?ur de la pand�mie |pdf=|usr=}}
| |
| − | {{tp|p=32336927|t=ä. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, History, Basic and Clinical Aspects |pdf=|usr=}}
| |
| − | {{tp|p=32371230|t=2020. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency |pdf=|usr=}}
| |
| − | {{tp|p=32344226|t=2020. COVID-19: Disease, management, treatment, and social impact |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Reviews on covid19 disease]]''' |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32327870|t=ä. Recomendaciones sobre el tratamiento antitromb�tico durante la pandemia COVID-19 Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Espa�ola de Cardiolog�a |pdf=|usr=}}
| |
| − | {{tp|p=32277760|t=2020. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis |pdf=|usr=}}
| |
| − | {{tp|p=32134111|t=2020. Understanding COVID-19 new diagnostic guidelines - a message of reassurance from an internal medicine doctor in Shanghai |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 24: |
Zeile 13: |
| | | | |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=C7187661|t=ä. Group Testing for SARS-CoV-2: Forward to the Past?|pdf=|usr=}}
| |
| − | {{tp|p=32329979|t=2020. COVID-19 rapid antibody cassette point of care tests: practical considerations |pdf=|usr=}}
| |
| − | {{ttp|p=32358057|t=2020. Overcoming the bottleneck to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection |pdf=|usr=}}
| |
| − | {{ttp|p=32373393|t=ä. Rapid and Sensitive Detection of COVID-19 Using CRISPR/Cas12a-based Detection with Naked Eye Readout, CRISPR/Cas12a-NER |pdf=|usr=}}
| |
| − | {{tp|p=32270436|t=ä. Detection of serum IgM and IgG for COVID-19 diagnosis |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32321099|t=ä. COVID-19 - Computed tomography findings in two patients in Petr�polis, Rio de Janeiro, Brazil |pdf=|usr=}}
| |
| − | {{tp|p=32267461|t=ä. Chest radiography and computed tomography findings from a Brazilian patient with COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32215898|t=2020. CT-Morphologie von COVID-19: Fallbeispiel und Literaturubersicht |pdf=|usr=}}
| |
| − | {{tp|p=32193883|t=2020. CT appearance of severe, laboratory-proven coronavirus disease 2019 (COVID-19) in a Caucasian patient in Berlin, Germany |pdf=|usr=}}
| |
| − | {{tp|p=32241067|t=2020. Clinics in Diagnostic Imaging: COVID-19 atypical pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32312025|t=2020. Variable computed tomography appearances of COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| − | ----
| + | |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32269081|t=2020. Phylogenetic network analysis of SARS-CoV-2 genomes |pdf=|usr=}}
| |
| − | {{tp|p=32009228|t=2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission |pdf=|usr=}}
| |
| − | {{tp|p=32277040|t=2020. Structure of the RNA-dependent RNA polymerase from COVID-19 virus |pdf=|usr=}}
| |
| − | {{tp|p=32075877|t=2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32165541|t=2020. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells |pdf=|usr=}}
| |
| − | {{tp|p=32364961|t=2020. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?|pdf=|usr=}}
| |
| − | {{tp|p=32245784|t=2020. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV |pdf=|usr=}}
| |
| − | {{tp|p=32366695|t=ä. Site-specific glycan analysis of the SARS-CoV-2 spike |pdf=|usr=}}
| |
| − | {{tp|p=32132184|t=2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − | {{ttp|p=32291557|t=ä. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells |pdf=|usr=}}
| |
| − | {{tp|p=32347055|t=2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32304647|t=2020. SARS-CoV-2 shedding and infectivity |pdf=|usr=}}
| |
| − | {{tp|p=32304646|t=ä. SARS-CoV-2 shedding and infectivity ? Authors reply |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 72: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32292530|t=2020. Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan|pdf=|usr=}}
| + | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32226636|t=2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study |pdf=|usr=}}
| |
| − | {{tp|p=32298458|t=2020. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?|pdf=|usr=}}
| |
| | | | |
| | | | |
| − | ----
| + | |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32326988|t=ä. Lactose Dehydrogenase in Patients with Severe COVID-19: A Meta-Analysis of Retrospective Study }}
| |
| − | {{tp|p=32339247|t=ä. Does apolipoprotein E genotype predict COVID-19 severity?|pdf=|usr=}}
| |
| − | {{tp|p=32371949|t=2020. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| − | {{tp|p=32303993|t=ä. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids |pdf=|usr=}}
| + | |
| − | {{tp|p=32303590|t=2020. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Similar diseases and pathomechanisms]]''' | | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32342879|t=ä. COVID-19 and radiation induced pneumonitis: overlapping clinical features of different diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32202647|t=2020. Mimics and chameleons of COVID-19 |pdf=|usr=}}
| + | |
| − | ----
| + | |
| | | | |
| | | | |
| Zeile 99: |
Zeile 53: |
| | | | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| − | {{tp|p=32222804|t=ä. Arthralgia as an initial presentation of COVID-19: observation |pdf=|usr=}}
| |
| | | | |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| − | {{tp|p=32192233|t=2020. Co-infection with SARS-CoV-2 and Human Metapneumovirus |pdf=|usr=}}
| |
| − | {{tp|p=32170625|t=ä. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients |pdf=|usr=}}
| |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32356640|t=2020. SARS-CoV-2 pneumonia and pulmonary embolism in a 66-year-old female |pdf=|usr=}}
| + | |
| − | {{tp|p=32329980|t=2020. SARS-CoV-2 infection masquerading as a possible pulmonary embolism |pdf=|usr=}}
| + | |
| − | {{tp|p=32351657|t=ä. Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32294340|t=ä. Immune Thrombocytopenic Purpura in a Patient with Covid-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Microvascular]]'''
| |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32372844|t=ä. COVID-19 y tratamiento guiado con tests de diagn�stico bioqu�micos y moleculares para reducir el da�o cardiaco y la cardiotoxicidad |pdf=|usr=}}
| |
| − | {{tp|p=32355394|t=ä. COVID-19 y shock cardiog�nico: diferentes formas de presentaci�n cardiovascular con alta mortalidad |pdf=|usr=}}
| |
| − | {{tp|p=32345547|t=ä. Fulminant myocarditis due to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32267110|t=2020. COVID-19 et maladies cardiovasculaires |pdf=|usr=}}
| |
| − | {{tp|p=32227794|t=2020. At the heart of the COVID-19 outbreak: early cardiac implications and mitigating strategies |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32329044|t=2020. Complicaciones neurologicas por coronavirus y COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32359804|t=ä. Covid-19 and Guillain-Barr� syndrome: More than a coincidence!|pdf=|usr=}}
| |
| − | {{tp|p=32334841|t=ä. COVID-19 may induce Guillain-Barr� syndrome |pdf=|usr=}}
| |
| − | {{tp|p=32246403|t=ä. The brain, another potential target organ, needs early protection from SARS-CoV-2 neuroinvasion |pdf=|usr=}}
| |
| − | {{tp|p=32344366|t=2020. Focal status epilepticus as unique clinical feature of COVID-19: A case report |pdf=|usr=}}
| |
| − | {{tp|p=32366614|t=2020. Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| | + | |
| | | | |
| | | | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32328338|t=2020. Anal swab findings in an infant with COVID?19 |pdf=|usr=}}
| |
| − | {{tp|p=32356641|t=2020. Addressing multiple gastroenterological aspects of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32250094|t=2020. Gastrointestinal symptoms as the first, atypical indication of severe acute respiratory syndrome coronavirus 2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32343593|t=2020. COVID-19, coronavirus, SARS-CoV-2 and the small bowel |pdf=|usr=}}
| |
| − | {{tp|p=32376072|t=ä. Beware: Gastrointestinal symptoms can be a manifestation of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32353720|t=2020. COVID-19 faecal-oral transmission: Are we asking the right questions?|pdf=|usr=}}
| |
| − | {{tp|p=32358202|t=ä. SARS-CoV-2 productively infects human gut enterocytes |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| − | | + | *'''[[The morbid survivor]]''' |
| − | *'''[[Kidney, urology]]''' | + | |
| − | {{tp|p=32362571|t=2020. SARS-CoV-2 and the testis: similarity with other viruses and routes of infection |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=C7129713|t=ä. Coronavirus: la emergencia geri�trica de 2020 Documento conjunto de la Secci�n de Cardiolog�a Geri�trica de la Sociedad Espa�ola de Cardiolog�a y la Sociedad Espa�ola de Geriatr�a y Gerontolog�a |pdf=|usr=}}
| |
| − | {{tp|p=C7151242|t=ä. Controversy regarding ACE inhibitors / ARBs in Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32331829|t=ä. Smoking and coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32362357|t=ä. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum |pdf=|usr=}}
| |
| − | {{tp|p=32314010|t=ä. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs |pdf=|usr=}}
| |
| − | {{tp|p=32346493|t=ä. Clinical presentations and outcomes of SARS-CoV-2 infected pneumonia in pregnant women and health status of their neonates |pdf=|usr=}}
| |
| − | {{tp|p=32335406|t=ä. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| − |
| |
| − | *'''[[The morbid survivor]]'''
| |
| − | {{tp|p=32360909|t=ä. Follow-up studies in COVID-19 recovered patients - is it mandatory?|pdf=|usr=}}
| |
| | | | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| − | {{tp|p=32312026|t=2020. An elderly couple with COVID-19 pneumonia treated in Singapore: contrasting clinical course and management |pdf=|usr=}}
| |
| − | {{tp|p=32277836|t=2020. Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Case series]]'''
| |
| − | {{tp|p=32146694|t=ä. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China |pdf=|usr=}}
| |
| − | {{ttp|p=32048163|t=2020. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury |pdf=|usr=}}
| |
| − | *'''[[Registries]]'''
| |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| − | *'''[[Trials]]'''
| |
| − | *'''[[Candidate Compounds Covid19]]'''
| |
| − | {{tp|p=32239125|t=2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32256547|t=2020. Clinical trials on drug repositioning for COVID-19 treatment |pdf=|usr=}}
| |
| − | {{tp|p=32267301|t=ä. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes |pdf=|usr=}}
| |
| − | {{tp|p=32232552|t=ä. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs |pdf=|usr=}}
| |
| − | {{tp|p=32124179|t=ä. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need |pdf=|usr=}}
| |
| − | {{tp|p=32376987|t=2020. Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression |pdf=|usr=}}
| |
| − | {{tp|p=32278175|t=ä. COVID-19: A promising cure for the global panic |pdf=|usr=}}
| |
| − | {{tp|p=32253226|t=ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}}
| |
| − | {{tp|p=32358203|t=ä. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir |pdf=|usr=}}
| |
| − | {{tp|p=32198291|t=2020. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors |pdf=|usr=}}
| |
| − | {{tp|p=32321856|t=ä. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease |pdf=|usr=}}
| |
| − | {{tp|p=32347055|t=2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors |pdf=|usr=}}
| |
| − | {{tp|p=32341331|t=2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32347054|t=2020. Strategies for vaccine development of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32133159|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32366290|t=2020. Mesenchymal stem cells as a potential therapy for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=C7110269|t=ä. COVID-19 Outbreak: an Update on Therapeutic Options |pdf=|usr=}}
| |
| − | {{tp|p=32307653|t=ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement |pdf=|usr=}}
| |
| − | {{tp|p=32281052|t=ä. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future |pdf=|usr=}}
| |
| − | {{tp|p=32320535|t=2020. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32362735|t=ä. Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a computer-aided study |pdf=|usr=}}
| |
| − | {{tp|p=32347963|t=2020. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32343358|t=2020. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Case series]]''' |
| | | | |
| | | | |
| | + | *'''[[Registries]]''' |
| | | | |
| − | ----
| |
| | | | |
| | + | *'''[[Trials]]''' |
| | | | |
| − | *'''[[Other routes of infection]]''' | + | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32291098|t=ä. Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Biophysics of aerosols]]'''
| |
| | | | |
| − | *'''[[Passive protective equipment]]''' | + | *'''[[Other routes of infection]]''' |
| − | {{ttp|p=32322159|t=ä. Electrostatic Charged Nanofiber Filter for Filtering Airborne Novel Coronavirus (COVID-19) and Nano-aerosols |pdf=|usr=}}
| + | |
| − | {{ttp|p=32372877|t=2020. Charged PVDF multilayer nanofiber filter in filtering simulated airborne novel coronavirus (COVID-19) using ambient nano-aerosols |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Running your hospital]]''' | + | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32372843|t=ä. Telecardiolog�a en tiempos de la pandemia COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32338017|t=2020. COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32316737|t=2020. Resumption of activity in gastroenterology departments Recommendations by SEPD, AEEH, GETECCU and AEG |pdf=|usr=}}
| + | |
| − | {{tp|p=32202911|t=2020. Recommendations by the SEPD and AEG, both in general and on the operation of gastrointestinal endoscopy and gastroenterology units, concerning the current SARS-CoV-2 pandemic (March, 18) |pdf=|usr=}}
| + | |
| − | {{tp|p=32329046|t=2020. Documento EMCAM (Esclerosis Multiple Comunidad Autonoma de Madrid) para el manejo de pacientes con esclerosis multiple durante la pandemia de SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32329045|t=2020. Herramientas de salud digital para superar la brecha de atencion en epilepsia antes, durante y despues de la pandemia de COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32303331|t=2020. Covid-19, the pandemic war: Implication for neurologists |pdf=|usr=}}
| + | |
| − | {{tp|p=32354651|t=ä. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network |pdf=|usr=}}
| + | |
| − | {{tp|p=32320999|t=2020. CHALLENGES IN THE FIGHT AGAINST THE COVID-19 PANDEMIC IN UNIVERSITY HOSPITALS |pdf=|usr=}}
| + | |
| − | {{ttp|p=C7102575|t=ä. Preventing intra-hospital infection and transmission of COVID-19 in healthcare workers |pdf=|usr=}}
| + | |
| − | {{tp|p=32292260|t=2020. Guidelines for dental care provision during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32341229|t=2020. Saudi association for the study of liver diseases and transplantation position statement on liver transplantation during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32343342|t=ä. The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders |pdf=|usr=}}
| + | |
| − | {{tp|p=32345478|t=ä. Is schizophrenia research relevant during the COVID-19 pandemic?|pdf=|usr=}}
| + | |
| − | {{tp|p=32349886|t=ä. Long-acting injectable antipsychotics treatment during COVID-19 pandemic ? A new challenge |pdf=|usr=}}
| + | |
| − | {{tp|p=32299718|t=ä. Ecosystem approaches to the risk for schizophrenia |pdf=|usr=}}
| + | |
| − | {{tp|p=32327314|t=ä. COVID-19, mobile health and serious mental illness |pdf=|usr=}}
| + | |
| − | {{tp|p=32370129|t=2020. Blockchain-Based Healthcare Workflow for Tele-Medical Laboratory in Federated Hospital IoT Clouds |pdf=|usr=}}
| + | |
| − | {{tp|p=32349198|t=2020. Chapter of Gastroenterologists professional guidance for management of patients with liver disease in Singapore during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32241064|t=2020. A call to arms: a perspective of safe general surgery in Singapore during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32241065|t=2020. Chapter of Gastroenterologists professional guidance on risk mitigation for gastrointestinal endoscopy during COVID-19 pandemic in Singapore |pdf=|usr=}}
| + | |
| − | {{tp|p=32227793|t=2020. Dealing with COVID-19: initial perspectives of a small radiology department |pdf=|usr=}}
| + | |
| − | {{tp|p=32349195|t=2020. Deeply reconsidering elective surgery: worldwide concerns regarding colorectal surgery in a COVID-19 pandemic and a Singapore perspective |pdf=|usr=}}
| + | |
| − | {{tp|p=32312024|t=2020. Trauma and orthopaedics in the COVID-19 pandemic: breaking every wave |pdf=|usr=}}
| + | |
| − | {{tp|p=32299184|t=2020. COVID-19 - where do we go from here?|pdf=|usr=}}
| + | |
| − | {{tp|p=32299183|t=2020. Striving as a nation to become an academic leader in the COVID-19 crisis |pdf=|usr=}}
| + | |
| − | {{tp|p=32283886|t=2020. Love in the time of coronavirus: training and service during COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32279480|t=2020. Impact of COVID 19: perspectives from gastroenterology |pdf=|usr=}}
| + | |
| − | {{tp|p=32361216|t=2020. Sleep problems and medical isolation during the SARS-CoV-2 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32361215|t=2020. Delirium and sleep disturbances in COVID?19: a possible role for melatonin in hospitalized patients?|pdf=|usr=}}
| + | |
| − | {{tp|p=32371939|t=ä. Impact of COVID-19 outbreak on spinal pathology: single center first impression |pdf=|usr=}}
| + | |
| − | {{tp|p=32346122|t=2020. Lessons learned from the coronavirus disease 2019 (Covid-19) outbreak in a monographic center for spinal cord injury |pdf=|usr=}}
| + | |
| − | {{tp|p=32317765|t=ä. COVID-19: the risk of respiratory techniques in healthcare workers |pdf=|usr=}}
| + | |
| − | {{tp|p=32303672|t=2020. COVID-19 tsunami: the first case of a spinal cord injury patient in Italy |pdf=|usr=}}
| + | |
| − | {{tp|p=32344060|t=ä. Spine Fellowship Training Reorganizing during a Pandemic: Perspectives from a Tertiary Orthopaedic Specialty Center in the Epicenter of Outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32296046|t=2020. COVID-19 and spinal cord injury and disease: results of an international survey |pdf=|usr=}}
| + | |
| − | {{tp|p=32243846|t=2020. Message from the Editor: Stem Cell Science in the Time of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32352910|t=2020. Endovascular Therapy for Patients With Acute Ischemic Stroke During the COVID-19 Pandemic: A Proposed Algorithm |pdf=|usr=}}
| + | |
| − | {{tp|p=32347790|t=2020. Mechanical Thrombectomy in the Era of the COVID-19 Pandemic: Emergency Preparedness for Neuroscience Teams: A Guidance Statement From the Society of Vascular and Interventional Neurology |pdf=|usr=}}
| + | |
| − | {{tp|p=32323016|t=ä. SAGES and EAES recommendations for minimally invasive surgery during COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32363070|t=2020. Even with COVID-19 neurosurgeons should still perform necessary urgent/emergent neurosurgery to avoid major permanent neurological deficits |pdf=|usr=}}
| + | |
| − | {{tp|p=32363053|t=2020. COVID-19 Provides An Opportunity to Reassess How Frequent and How Extensive Elective Spine Surgery Should Be |pdf=|usr=}}
| + | |
| − | {{tp|p=32367447|t=ä. (Laparoscopy)Detect to protect: pneumoperitoneum gas samples for SARS-CoV-2 and biohazard testing |pdf=|usr=}}
| + | |
| − | {{tp|p=32307095|t=ä. Response to COVID-19 by the surgical community |pdf=|usr=}}
| + | |
| − | {{tp|p=32299626|t=ä. COVID-19: How can a department of general surgery survive in a pandemic?|pdf=|usr=}}
| + | |
| − | {{tp|p=32208497|t=2020. COVID-19 pandemic: palliative care for elderly and frail patients at home and in residential and nursing homes |pdf=|usr=}}
| + | |
| − | {{tp|p=32208494|t=2020. COVID-19: decision making and palliative care |pdf=|usr=}}
| + | |
| − | {{tp|p=32208495|t=2020. COVID-19 pandemic: triage for intensive-care treatment under resource scarcity |pdf=|usr=}}
| + | |
| − | {{tp|p=32208493|t=2020. Recommendations for the admission of patients with COVID-19 to intensive care and intermediate care units (ICUs and IMCUs) |pdf=|usr=}}
| + | |
| − | {{tp|p=32352150|t=2020. Age, comorbidity, frailty status: effects on disposition and resource allocation during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32271935|t=2020. Response of a European surgical department to the COVID-19 crisis |pdf=|usr=}}
| + | |
| − | {{tp|p=32330285|t=2020. Interventional radiology workflow during the COVID-19 pandemic: recommendations of the Swiss Society of Vascular and Interventional Radiology |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Mental aspects of health professionals]]'''
| |
| | | | |
| | + | *'''[[Passive protective equipment]]''' |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Running your hospital]]''' |
| | | | |
| | | | |
| | + | *'''[[Mental aspects of health professionals]]''' |
| | | | |
| | + | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | | | |
| | | | |
| | | | |
| − | *'''[[Socio-psychiatric aspects of the status hygienicus]]'''
| |
| − | {{tp|p=32336835|t=ä. From the Editor of Sexuality and Disability: The Impact of COVID-19 on Sexuality and Disability?Are We Closer or More Isolated?|pdf=|usr=}}
| |
| − | {{tp|p=32241071|t=2020. Narrative synthesis of psychological and coping responses towards emerging infectious disease outbreaks in the general population: practical considerations for the COVID-19 pandemic |pdf=|usr=}}
| |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32283124|t=ä. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| Zeile 305: |
Zeile 138: |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32242087|t=ä. What the stock market tells us about the post-COVID-19 world |pdf=|usr=}}
| |
| − | {{tp|p=32313382|t=ä. Can Global Pharmaceutical Supply Chains Scale Up Sustainably for the COVID-19 Crisis?|pdf=|usr=}}
| |
| − | {{tp|p=32313383|t=2020. A brave new world: Lessons from the COVID-19 pandemic for transitioning to sustainable supply and production |pdf=|usr=}}
| |
| − | {{tp|p=32304970|t=2020. Challenges and solutions for addressing critical shortage of supply chain for personal and protective equipment (PPE) arising from Coronavirus disease (COVID19) pandemic ? Case study from the Republic of Ireland |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Educational aspects of the status hygienicus]]''' | | *'''[[Educational aspects of the status hygienicus]]''' |
| − | {{tp|p=32313309|t=ä. Education and the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32302818|t=2020. Impact Of Sars-Cov-2 And Its Reverberation In Global Higher Education And Mental Health |pdf=|usr=}}
| |
| − |
| |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32300261|t=2020. Severe air pollution events not avoided by reduced anthropogenic activities during COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32333993|t=ä. Does the pathogenesis of SAR-CoV-2 virus decrease at high-altitude?|pdf=|usr=}}
| |
| − | {{tp|p=32304942|t=2020. Impact of meteorological factors on the COVID-19 transmission: A multi-city study in China |pdf=|usr=}}
| |
| − | {{tp|p=32375105|t=2020. Effect of lockdown amid COVID-19 pandemic on air quality of the megacity Delhi, India |pdf=|usr=}}
| |
| − | {{tp|p=32361460|t=2020. Effects of temperature and humidity on the daily new cases and new deaths of COVID-19 in 166 countries |pdf=|usr=}}
| |
| − | {{tp|p=32361428|t=2020. The impact of COVID-19 partial lockdown on the air quality of the city of Rio de Janeiro, Brazil |pdf=|usr=}}
| |
| − | {{tp|p=32361458|t=2020. Sunlight exposure increased Covid-19 recovery rates: A study in the central pandemic area of Indonesia |pdf=|usr=}}
| |
| − | {{tp|p=32353724|t=2020. Association between climate variables and global transmission oF SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32361443|t=2020. Temperature significantly changes COVID-19 transmission in (sub)tropical cities of Brazil |pdf=|usr=}}
| |
| − | {{tp|p=32353722|t=2020. Air quality status during 2020 Malaysia Movement Control Order (MCO) due to 2019 novel coronavirus (2019-nCoV) pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32339844|t=ä. Impact of temperature on the dynamics of the COVID-19 outbreak in China |pdf=|usr=}}
| |
| − | {{tp|p=32361118|t=2020. A spatio-temporal analysis for exploring the effect of temperature on COVID-19 early evolution in Spain |pdf=|usr=}}
| |
| − | {{tp|p=32348946|t=2020. A preliminary assessment of the impact of COVID-19 on environment ? A case study of China |pdf=|usr=}}
| |
| − | {{tp|p=32335409|t=2020. Effect of restricted emissions during COVID-19 on air quality in India |pdf=|usr=}}
| |
| − | {{tp|p=32335408|t=2020. Environmental perspective of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32335407|t=2020. The sensitivity and specificity analyses of ambient temperature and population size on the transmission rate of the novel coronavirus (COVID-19) in different provinces of Iran |pdf=|usr=}}
| |
| − | {{tp|p=32334160|t=2020. Effect of weather on COVID-19 spread in the US: A prediction model for India in 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32334164|t=ä. COVID-19 pandemic and environmental pollution: A blessing in disguise?|pdf=|usr=}}
| |
| − | {{tp|p=32334159|t=ä. Indirect effects of COVID-19 on the environment |pdf=|usr=}}
| |
| − | {{tp|p=32334158|t=ä. Impact of weather on COVID-19 pandemic in Turkey |pdf=|usr=}}
| |
| − | {{tp|p=32334162|t=2020. Correlation between climate indicators and COVID-19 pandemic in New York, USA |pdf=|usr=}}
| |
| − | {{tp|p=32335405|t=2020. COVID-19 transmission in Mainland China is associated with temperature and humidity: A time-series analysis |pdf=|usr=}}
| |
| − | {{tp|p=32361432|t=ä. Investigation of effective climatology parameters on COVID-19 outbreak in Iran |pdf=|usr=}}
| |
| − | {{tp|p=32315907|t=2020. What do we know about the SARS-CoV-2 coronavirus in the environment?|pdf=|usr=}}
| |
| − | {{tp|p=32315904|t=ä. Association between short-term exposure to air pollution and COVID-19 infection: Evidence from China |pdf=|usr=}}
| |
| − | {{tp|p=32302812|t=2020. Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality |pdf=|usr=}}
| |
| − | {{tp|p=32302810|t=ä. Changes in air quality during the lockdown in Barcelona (Spain) one month into the SARS-CoV-2 epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32269068|t=2020. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS?coronavirus 2 |pdf=|usr=}}
| |
| − | {{tp|p=32296757|t=ä. Air Pollution and the Novel Covid-19 Disease: a Putative Disease Risk Factor |pdf=|usr=}}
| |
| − | {{tp|p=32176808|t=2020. Potential impact of seasonal forcing on a SARS-CoV-2 pandemic |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32267109|t=2020. Coronavirus et COVID-19 : le point sur une pandemie galopante |pdf=|usr=}}
| |
| − | {{tp|p=32294667|t=ä. Translating transmissibility measures into recommendations for coronavirus prevention |pdf=|usr=}}
| |
| − | {{tp|p=32236385|t=ä. Outbreak investigation in cargo ship in times of COVID-19 crisis, Port of Santos, Brazil |pdf=|usr=}}
| |
| − | {{tp|p=32320998|t=ä. COVID-19 in Brazil: advantages of a socialized unified health system and preparation to contain cases |pdf=|usr=}}
| |
| − | {{tp|p=32215461|t=ä. The value of mitigating epidemic peaks of COVID-19 for more effective public health responses |pdf=|usr=}}
| |
| − | {{ttp|p=32296266|t=ä. Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32373394|t=ä. Using the contact network model and Metropolis-Hastings sampling to reconstruct the COVID-19 spread on the ?Diamond Princess? |pdf=|usr=}}
| |
| − | {{tp|p=32292631|t=ä. The inflection point about COVID-19 may have passed |pdf=|usr=}}
| |
| − | {{tp|p=32288968|t=2020. A data driven time-dependent transmission rate for tracking an epidemic: a case study of 2019-nCoV |pdf=|usr=}}
| |
| − | {{tp|p=32296594|t=ä. A systematic approach is needed to contain COVID-19 globally |pdf=|usr=}}
| |
| − | {{tp|p=32210236|t=2020. Epidemiological data from the COVID-19 outbreak, real-time case information |pdf=|usr=}}
| |
| − | {{tp|p=32334207|t=2020. Real-time estimation and prediction of mortality caused by COVID-19 with patient information based algorithm |pdf=|usr=}}
| |
| − | {{tp|p=32304973|t=2020. Evaluation of the lockdowns for the SARS-CoV-2 epidemic in Italy and Spain after one month follow up |pdf=|usr=}}
| |
| − | {{tp|p=32283308|t=2020. A field indoor air measurement of SARS-CoV-2 in the patient rooms of the largest hospital in Iran |pdf=|usr=}}
| |
| − | {{tp|p=32361455|t=2020. Modelling spatial variations of coronavirus disease (COVID-19) in Africa |pdf=|usr=}}
| |
| − | {{tp|p=32375067|t=ä. Prediction of the COVID-19 spread in African countries and implications for prevention and controls: A case study in South Africa, Egypt, Algeria, Nigeria, Senegal and Kenya |pdf=|usr=}}
| |
| − | {{tp|p=32361446|t=2020. SutteARIMA: Short-term forecasting method, a case: Covid-19 and stock market in Spain |pdf=|usr=}}
| |
| − | {{tp|p=32371231|t=2020. Computational analysis of SARS-CoV-2/COVID-19 surveillance by wastewater-based epidemiology locally and globally: Feasibility, economy, opportunities and challenges |pdf=|usr=}}
| |
| − | {{tp|p=32336562|t=ä. Restructured society and environment: A review on potential technological strategies to control the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32339832|t=2020. Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India |pdf=|usr=}}
| |
| − | {{tp|p=32334157|t=ä. Prediction for the spread of COVID-19 in India and effectiveness of preventive measures |pdf=|usr=}}
| |
| − | {{tp|p=32334161|t=2020. Can we predict the occurrence of COVID-19 cases? Considerations using a simple model of growth |pdf=|usr=}}
| |
| − | {{tp|p=32330703|t=2020. Effectiveness of the measures to flatten the epidemic curve of COVID-19 The case of Spain |pdf=|usr=}}
| |
| − | {{tp|p=32371477|t=ä. Rapid implementation of mobile technology for real-time epidemiology of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32234804|t=2020. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China |pdf=|usr=}}
| |
| − | {{tp|p=32234805|t=2020. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing |pdf=|usr=}}
| |
| − | {{tp|p=32213647|t=ä. The effect of human mobility and control measures on the COVID-19 epidemic in China |pdf=|usr=}}
| |
| − | {{tp|p=32179701|t=ä. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) |pdf=|usr=}}
| |
| − | {{tp|p=32144116|t=2020. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32350060|t=ä. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China |pdf=|usr=}}
| |
| − | {{tp|p=32269067|t=2020. Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China |pdf=|usr=}}
| |
| − | {{tp|p=32291278|t=ä. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period |pdf=|usr=}}
| |
| − | {{tp|p=32211911|t=2020. A midpoint perspective on the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=C7139267|t=ä. Determining the spatial effects of COVID-19 using the spatial panel data model |pdf=|usr=}}
| |
| − | {{tp|p=32292884|t=ä. Important Steps to Control COVID-19/SARS-CoV-2 Infection |pdf=|usr=}}
| |
| − | {{tp|p=C7113380|t=ä. On a Statistical Transmission Model in Analysis of the Early Phase of COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32191813|t=2020. COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation |pdf=|usr=}}
| |
| − | {{tp|p=32365217|t=2020. Reproductive number of the COVID-19 epidemic in Switzerland with a focus on the Cantons of Basel-Stadt and Basel-Landschaft |pdf=|usr=}}
| |
| − | {{tp|p=32031234|t=2020. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution |pdf=|usr=}}
| |
| − | {{tp|p=32227799|t=2020. Preliminary case report on the SARS-CoV-2 cluster in the UK, France, and Spain|pdf=|usr=}}
| |
| − | {{tp|p=32333603|t=2020. Transmission risk of SARS-CoV-2 to healthcare workers -observational results of a primary care hospital contact tracing |pdf=|usr=}}
| |
| − | {{tp|p=32343357|t=2020. The global COVID-19 response must include refugees and migrants |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]'''
| |
| − | {{tp|p=32308203|t=2020. Patients with respiratory symptoms are at greater risk of COVID-19 transmission |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Failure of executive measures]]'''
| |
| | | | |
| | | | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | | | |
| | + | |
| | + | |
| | + | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=C7111621|t=ä. Science Education in the Era of a Pandemic: How Can History, Philosophy and Sociology of Science Contribute to Education for Understanding and Solving the Covid-19 Crisis?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32203324|t=ä. COVID-19 and the crisis of national development |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 419: |
Zeile 170: |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32088858|t=ä. Puzzle of highly pathogenic human coronaviruses (2019-nCoV) |pdf=|usr=}}
| + | *'''[[misc.]]''' |
| − | {{tp|p=32334163|t=2020. Overview of Covid-19; its prevention and management in the light of Unani medicine |pdf=|usr=}}
| + | |
| − | {{tp|p=32335410|t=2020. COVID-19 outbreak: Migration, effects on society, global environment and prevention |pdf=|usr=}}
| + | |
| − | {{ttp|p=32296735|t=ä. Prudently conduct the engineering and synthesis of the SARS-CoV-2 virus |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[misc.]]'''
| |
| − | {{tp|p=32361911|t=ä. Single-cell transcriptome analysis of the novel coronavirus (SARS-CoV-2) associated gene ACE2 expression in normal and non-obstructive azoospermia (NOA) human male testes |pdf=|usr=}}
| |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| | | | |
| | | | |
| | | | |
| − | *'''[[PrePrint scene''']] | + | |
| − | *[https://prelights.biologists.com/ prelights]
| + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[lifechemicals.com antiviral candidate drugs]
| + | |
| − | *[biomol.com assays cytokines general spectrum]
| + | |
| − | *[labospace.com custom single probe assay 400 possible cytokines and so on]
| + | |
| − | *[codexdna.com dna synthesis]
| + | |
| − | *[eclipsebio.com around rna]
| + | |
| − | *[btbemulsions.com freud adjuvant kit]
| + | |
| − | *[biophysics.com div.]
| + | |
| − | *[molecular-machines.com microdissection]
| + | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
